Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 4 years ago

Possible Interaction: Glucose and Linagliptin

supplement:

Glucose

Research Papers that Mention the Interaction

Linagliptin also produced statistically significant dose-dependent reductions from baseline for glucose area under the effect curve over 3 hours after meal tolerance tests (-29.0 to -68.1 mg × h/dL; P < 0.05 for all 3 linagliptin groups).
Clinical therapeutics  •  2011  |  View Paper
Furthermore, linagliptin treatment for 3 months reduced serum levels of both glucose and insulin at 2 h, relative to voglibose, in the age-, sex-, and baseline-adjusted model.
Heart and Vessels  •  2018  |  View Paper
The data in Table 4 show that compared with placebo, linagliptin monotherapy reduced postprandial glucose by −1.95 mmol/l (95% CI: −5.14, −1.24) [1].
Diabetes, obesity & metabolism  •  2012  |  View Paper
In this study, monotherapy with either APD668 or linagliptin caused a reduction in the levels of ALT, AST, glucose , cholesterol and epididymal fat mass but the effect was more pronounced upon treatment with combination of both drugs.
Biochemical and biophysical research communications  •  2018  |  View Paper
Conclusion Linagliptin and liraglutide inhibit glucose- and Ang II-induced collagen formation in cardiac fibroblasts via activation of the ERK/NF-κB/pathway.
Acta Pharmacologica Sinica  •  2016  |  View Paper
Glycated hemoglobin (−0.22%; P = 0.0021), fasting plasma glucose (−0.6 mmol/L; P = 0.0283), and glucose (AUEC0–3h) (−5.9 mmol/h/L; P < 0.0001) improved significantly with linagliptin versus placebo.
Diabetes Therapy  •  2012  |  View Paper